Aminoglycoside-induced sensorineural hearing loss in pediatric cystic fibrosis patients: A retrospective cohort study

• Published in: Heliyon Vol. 10; no. 3; p. e25190
• Main Authors: Jouret, N, Van der Poel, N, Verhulst, S, Lammers, MJW, Van Rompaey, V, Jacquemin, L, Van Hoorenbeeck, K
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 15-02-2024; Elsevier
• Subjects: Aminoglycoside; Cystic fibrosis; Ototoxicity; Pediatric; Sensorineural hearing loss; Cystic fibrosis; Pediatric; Aminoglycoside; Sensorineural hearing loss; Ototoxicity
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2024.e25190

Pulmonary infections by gram-negative organisms are important in cystic fibrosis (CF). Aminoglycosides (AG) are often part of the treatment regimen. However, they are a well-known cause of ototoxicity. Even minimal hearing impairment in children could have a future impact on functional well-being.
We aimed to investigate the progression of sensorineural hearing loss (SNHL) over several years in pediatric CF patients, and to identify risk factors, such as the use of AG, including both intravenous (IV) and inhaled AG.
Retrospective analyses of patient records from children and adolescents followed up at the CF clinic of the Antwerp University Hospital, Belgium, were performed. We collected data on age, sex, pure-tone audiometry, and the use of AG. Descriptive and binary logistic regression analyses, and if indicated generalized estimating equations (GEE) analyses were performed.
Forty pediatric patients were enrolled in the study taking part from 2013 to 2020. Pure-tone audiometry revealed an important rate of SNHL over several years, with a prevalence of 29 % for high-frequency SNHL (i.e. 8 kHz). Increasing age was identified as a significant risk factor for the development of SNHL at 8 kHz if 5 or more IV AG courses (p = 0.01) were reported or when IV AG were combined with inhaled AG (p = 0.002).
Age combined with the use of IV AG (≥5 courses or in combination with inhaled AG) are predictive for developing high-frequency SNHL (i.e. 8 kHz). We suggest routine annual hearing screening (incl. high-frequency thresholds) in CF patients, starting from childhood.